![]() | |
| 公司名 | BOC Sciences |
| 联系人 | Linna Green |
| 电 话 | +16314854226 |
| 手 机 | +16314854226 |
| 电子邮件 | info@bocsci.com |
| 网 址 | http://www.bocsci.com/ |
| 地 区 | 其他 |
| 邮 编 | 11967 |
在线询盘仅适合非紧急采购的情形,您需要留下收货地域,采购数量及联系方式。供应商在收到您的询盘信息后,会通过您留下的联系方式联络您。如果您希望立即和供应商交谈,请直接拨打供应商电话。供应商手机:+16314854226
| 中文名 | 艾乐替尼 |
| 英文名 | Alectinib |
| 别名 | 艾乐替尼;阿来替尼盐酸盐;9-乙基-6,6-二甲基-8-(4-吗啉哌啶-1-基)-11-氧代-6,11-二氢-5H-苯并[B]咔唑-3-甲腈;9-乙基-6,11-二氢-6,6-二甲基-8-[4-(4-吗啉基)-1-哌啶基]-11-氧代-5H-苯并[B]咔唑-3-甲腈 |
| CAS | 1256580-46-7 |
| EINECS | 821-541-6 |
| 化学式 | C30H34N4O2 |
| 分子量 | 482.62 |
| inchi | |
| 包装信息 | 200 mg |
| 价格 | $199 |
| 产品描述 | 艾乐替尼 Alectinib, marketed as Alecensa, is an oral drug that blocks the activity of anaplastic lymphoma kinase (ALK) and is used to treat non-small-cell lung cancer (NSCLC). Alectinib has a low potential for interactions. While it is metabolised by the liver enzyme CYP3A4, and blockers of this enzyme accordingly increase its concentrations in the body, they also decrease concentrations of the active metabolite M4, resulting in only a small overall effect. Conversely, CYP3A4 inducers decrease alectinib concentrations and increase M4 concentrations. Interactions via other CYP enzymes and transporter proteins cannot be excluded but are unlikely to be of clinical significance. |
| 产品链接 | http://www.bocsci.com/product/alectinib-cas-1256580-46-7-454466.html |
| 更新日期 | 2025-04-30 11:27:47 |